Recent Articles from Business Wire

Brera Holdings PLC (Nasdaq: SLMT) (the “Company” or “Solmate”) announced that Ron Sade, Chief Executive Officer, and Keren Maimon, Member of the Board of Directors (the “Board”), made a combined personal equity investment of more than $10 million in the Company through a registered direct offering of an aggregate of 2,298,000 Class B ordinary shares at a price of $4.97 per share, a premium to the current market price.

AstraZeneca advances its ambition to eliminate cancer as a cause of death and transform outcomes for people living with rare diseases with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 to June 2, 2026.

Manchester United is delighted to announce that Michael Carrick will continue as Head Coach of the men’s first-team, having signed a new contract which will run to 2028.

Granite Real Estate Investment Trust (TSX: GRT.UN) (“Granite REIT” or “Granite”) today announced the acceptance by the Toronto Stock Exchange (the “TSX”) of Granite’s Notice of Intention to Make a Normal Course Issuer Bid (“NCIB”). Pursuant to the NCIB, Granite proposes to purchase through the facilities of the TSX and any alternative trading system in Canada, from time to time over the next 12 months, if considered advisable, up to an aggregate of 6,038,313 of Granite REIT’s issued and outstanding units (the “Units”), being approximately 10% of Granite REIT’s public float of Units as of May 20, 2026. Pursuant to a previous notice of intention to conduct a NCIB, under which Granite REIT sought and received approval from the TSX to purchase up to 6,060,162 Units for the period of May 26, 2025 to May 25, 2026, Granite REIT has purchased, as of May 20, 2026, 237,536 Units on the open market at a weighted average purchase price of $69.2167 per Unit. As of May 20, 2026, Granite REIT had 60,713,130 Units issued and outstanding and a public float of 60,383,131 Units.

SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, today announced that the company and key collaborators will present data from three abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29 to June 2 in Chicago.

Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced it will showcase data across its portfolio of high-quality comprehensive genomic profiling tests at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29-June 2 in Chicago. Data from 14 abstracts will be presented on copy number loss detection, serial circulating tumor DNA (ctDNA) genomic profiling, Foundation Medicine’s proprietary homologous recombination deficiency signature (HRDsig) and more.

BJ’s Wholesale Club (NYSE: BJ) today announced that Fitch Ratings has assigned a first-time Long Term Issuer Default Rating of ‘BBB’ to the company. Fitch has also assigned BBB+ ratings to the company’s ABL revolving credit facility and secured term loan due 2029. The ratings carry a Stable Outlook.

This is an initial notification of transactions of persons discharging managerial responsibility (“PDMRs”) in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

BJ’s Wholesale Club Holdings, Inc. (NYSE: BJ) (the “Company”) today announced its financial results for the thirteen weeks ended May 2, 2026.

Booz Allen Hamilton Holding Corporation (NYSE: BAH), the parent company of advanced technology company Booz Allen Hamilton Inc., today announced preliminary results for the fourth quarter and full fiscal year 2026.

Natuzzi S.p.A. (NYSE: NTZ) (“Natuzzi” or the “Company”) announced today that on May 20, 2026, the New York Stock Exchange (the “NYSE”) notified the Company that it had accepted its plan to regain compliance with the NYSE’s continued listing standards.

Starfighters Space, Inc. (“Starfighters Space” or the “Company”) (NYSE American: FJET), the space company operating the world’s only commercial fleet of flight-ready MACH 2+ supersonic aircraft, today announced a $17.5 million strategic equity investment led by global institutional investors.

lululemon (NASDAQ:LULU) today announced the opening of the first lululemon stores in Greece through its franchise partnership with Arion Retail Group. The first store location will open tomorrow, Saturday, May 23, 2026, at Akadimias 17 & Voukourestiou in Kolonaki, central Athens. A second store location is set to open on Friday, June 12, 2026, at the Golden Hall shopping mall.

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2.

Karooooo (KARO), the global provider of mobility and operational intelligence solutions and parent company of Cartrack, today announced that Richard Schubert, Group Chief Operating Officer, and Paul Bieber, Vice President of Investor Relations and Strategic Finance, will participate in the 46th Annual William Blair Growth Stock Conference on Wednesday, June 3rd at 4:40 p.m. CT.

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations.

A vehicle controlled by DigitalBridge Group, Inc. (NYSE: DBRG) (“DigitalBridge”) and Aberdeen Investments has acquired Equans’ asset-based e-mobility activities in the Netherlands. The business specialises in delivering reliable, scalable, and sustainable e-mobility infrastructure.

LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Services business in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region.

Regulatory News:

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil.

The Institute for Global Environmental Strategies (IGES) is set to host the 18th International Forum for Sustainable Asia and the Pacific (ISAP2026). For the first time, ISAP will be held in Kansai under the overall theme, ‘Strengthening Local Resilience to Planetary Crises: Scaling up Synergistic Solutions’. The Plenary Sessions (hybrid) will take place on Wednesday, 22 July 2026, at the Lasse Hall in Kobe City, Hyogo Prefecture, while the Thematic Tracks* will be held online from August to October 2026.

Today marks the official release of “Something Special,” the highly anticipated cross-market collaboration from international star Ahn Hyo-seop and multi-platinum recording artist Khalid, available now via FANDOM on all major streaming platforms. Stream the single HERE. Musicow will also release an official music video in June, highlighting the unique chemistry between Ahn Hyo-seop and Khalid while bringing the song’s cross-cultural collaboration to life on screen.

Mitsubishi Electric Corporation (TOKYO: 6503) announced today that Tadakiyo Seki, an engineer at the company’s Engineering and Development Center in Japan, has been awarded the title of Kaggle Competitions Master by Kaggle, Inc., a Google LLC subsidiary and the world’s largest AI competition platform.

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Hub Group, Inc. (“Hub Group” or the “Company”) (NASDAQ:HUBG) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Wix.com Ltd. (“Wix” or the “Company”) (NASDAQ:WIX) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ:EMBC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Central District of California, captioned Elwan v. Veritone, Inc., et al., Case No. 8:26-cv-01275, on behalf of persons and entities that purchased or otherwise acquired Veritone, Inc. (“Veritone” or the “Company”) (NASDAQ: VERI) securities between October 14, 2025 and April 14, 2026, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Lenovo Group Limited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported fourth quarter and full year results for fiscal year 2025/26, marking an exceptional Q4 and the strongest year in the Group’s history. During the quarter, overall Group revenue reached an all-time fourth quarter high of US$21.6 billion, up 27% year-on-year, marking the highest year-on-year growth rate in five years, with adjusted net income[1] doubling year-on-year to US$559 million. AI-related revenue[2] stood out as a leading growth engine, growing 84% year-on-year to account for 38% of total Group revenue in Q4.

First Northern Bank is proud to announce that President and Chief Executive Officer Jeremiah Smith has been appointed to the Board of Directors of the Sierra College Foundation.

Burtech Acquisition Corp II (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing of its initial public offering of 8,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one redeemable warrant. Each whole warrant, which becomes exercisable 30 days after the completion of the Company’s initial business combination, will entitle the holder thereof to purchase one Class A ordinary share at $11.50 per share, subject to adjustments. The units are expected to trade on The Nasdaq Stock Market LLC (“Nasdaq”) under the ticker symbol “BRKHU” beginning May 22, 2026. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and the warrants are expected to be traded on Nasdaq under the symbols “BRKH” and “BRKHW,” respectively.

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Black Rock Coffee Bar, Inc. (“Black Rock Coffee” or the “Company”) (NASDAQ:BRCB) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

The law firm of Kirby McInerney LLP is investigating potential claims against AECOM (“AECOM” or the “Company”) (NYSE:ACM). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Armstrong World Industries, Inc. (“Armstrong World” or the “Company”) (NYSE:AWI) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of The Marzetti Company (“Marzetti” or the “Company”) (NASDAQ:MZTI) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

KBRA assigns preliminary ratings to 10 classes of mortgage pass-through notes from J.P. Morgan Mortgage Trust 2026-4MPR (JPMMT 2026-4MPR). The pool comprises 248 first-lien, fixed rate residential mortgage loans with an aggregate principal balance of $333.5 million as of the cut-off date. The pool includes both non-agency (93.9%) and agency-eligible (6.1%) loans. The weighted average original credit score is 760, which is well within the prime mortgage range.

Lightmatter, the leader in photonic (super)computing, today announced Guide® DR, a high-density laser in an innovative Laser Network Interface Card (“LNIC”) form factor built to OCP NIC 3.0 dimensions. The Guide DR LNIC is a modular, high-density laser array that enables approximately four times the rack density of conventional External Laser Small Form Factor Pluggables (ELSFPs). By relocating the light source from the faceplate into the chassis, the Guide DR LNIC solves the faceplate scaling bottleneck while leveraging existing liquid cooling infrastructure. Guide DR was specifically designed to support Passage® L20 and other high-bandwidth optical interconnects. This provides AI factories the integration flexibility and performance required to drive scale-up clusters to one thousand XPUs and beyond.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22.

KBRA assigns a long-term AA- rating to Miami-Dade County (the County), Florida, Aviation Revenue Refunding Bonds, Series 2026A (AMT) and Aviation Revenue Refunding Bonds Series 2026B (Non-AMT) issued for Miami International Airport (MIA). Concurrently, KBRA affirms the AA- rating on the County's approximately $5.1 billion Aviation Revenue Bonds outstanding. The Outlook remains Positive.

Veracyte, Inc. (NASDAQ: VCYT), a leading cancer diagnostics company, announced today that data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests will be presented at the 2026 ASCO Annual Meeting in Chicago, taking place May 29 – June 2. The OPTIMA and ENZAMET trial presentations are expected to provide practice-changing evidence demonstrating how Veracyte’s genomic tests can guide treatment decisions in both early-stage breast cancer and metastatic prostate cancer.

Conduent Incorporated (Nasdaq: CNDT), a global technology‑driven business solutions and services provider, today announced that it has entered into a definitive agreement to sell its Public Transit business, an operating unit of Conduent Transportation, to Modaxo, a global technology organization focused on moving the world’s people. The Public Transit business consists of Transit Fare Management and Fleet Management Solutions businesses.

Halliburton Company (NYSE: HAL) announced today that its board of directors has declared a 2026 second quarter dividend of seventeen cents ($0.17) a share on the Company’s common stock payable on June 24, 2026, to shareholders of record at the close of business on June 3, 2026.

MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today that it will release the results of the MSCI 2026 Global Market Accessibility Review on June 18, 2026, and the results of the MSCI 2026 Annual Market Classification Review on June 23, 2026.

Four Corners Property Trust (NYSE:FCPT), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties (“FCPT” or the “Company”), is pleased to announce the acquisition of a Gerber Collision property for $3.5 million. The property is located in a highly trafficked corridor in North Carolina and corporate-operated under a triple net lease with approximately eight years of term remaining. The transaction was priced at a 7.5% cap rate on rent as of the closing date including rent credits received at closing and exclusive of transaction costs.

If you have suffered a loss on your New Era Energy & Digital, Inc. (“New Era” or the “Company”) (NASDAQ:NUAI) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

As organizations race to capture the benefits of artificial intelligence, research from FranklinCovey Institute reveals a critical obstacle: most employees feel they are navigating AI alone, without meaningful support or guidance. Eighty percent of individual contributors describe their manager’s approach to AI as “hands-off,” which underscores a widening gap between AI’s potential and how it’s actually used at work.

SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced that it filed its Annual Report on Form 10-K for Fiscal Year 2026, which ended March 31, 2026, with the U.S. Securities and Exchange Commission. It is available on Logitech's website at http://ir.logitech.com.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place May 29–June 2 in Chicago, IL.

Aulos Bioscience, a clinical-stage immuno-oncology company developing an immune-activating antibody therapeutic designed by leveraging an AI platform, today announced positive Phase 2 data from its ongoing Phase 1/2 study of imneskibart in patients with doublet checkpoint inhibitor (CPI)-refractory metastatic melanoma. The data will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting in Chicago, Illinois.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on the ASCO 2026 website. The abstract will be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) Rapid Oral Abstract Session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in Hall D1 of McCormick Place, Chicago.

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data from its oncology portfolio and pipeline at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting to be held May 29 – June 2 in Chicago, Illinois. Across more than 60 disclosures and 19 oral presentations, the Company will highlight progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies.

Agendia®, Inc., a leader in precision oncology for breast cancer, today announced new data to be presented at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 29 – June 2 in Chicago. The company will present two posters highlighting how MammaPrint® (MP) + BluePrint® (BP) provide biological insights into treatment response and help further refine therapeutic decision-making for patients with early-stage breast cancer (EBC).

Obsidian Therapeutics, Inc., a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced positive Phase 2 results in patients with advanced melanoma from the Phase 1/2 Agni-01 multicenter study of OBX-115. These data will be presented in an oral presentation by Allison S. Betof, M.D., Ph.D., FASCO, associate professor of medicine (oncology), Stanford School of Medicine, on Monday, June 1, 2026, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Dell Technologies (NYSE: DELL) announces that Arthur Lewis, president of Infrastructure Solutions Group, will present in a fireside chat at the following conference:

858 Therapeutics, a clinical-stage biotechnology company, today announced preliminary safety and efficacy data from its ongoing, first-in-human Phase 1/2 trial of PARG inhibitor ETX-19477. These data will be presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, May 30.

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of initial data from the randomized Phase 2 trial (Duravelo-2) evaluating zelenectide pevedotin (zelenectide) in previously untreated patients with metastatic urothelial cancer (mUC), demonstrating encouraging response rates and a potentially differentiated safety profile both as a monotherapy and in combination with pembrolizumab. In addition, updated data from the Phase 1 trial (Duravelo-1) in previously untreated, cisplatin-ineligible mUC patients demonstrated encouraging median progression-free survival (PFS) comparable to published data for standard of care (SOC). The data announced today will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2 in Chicago.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus’ multifunctional Fc-enhanced anti-CTLA-4 antibody, with balstilimab (BAL), an anti-PD-1 antibody, in patients with advanced cutaneous melanoma refractory or resistant to prior anti-PD-(L)1 therapy, including patients previously treated with anti-CTLA-4 therapy. The full dataset will be presented by Dr. Michael Atkins on May 31, 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Genmab A/S (Nasdaq: GMAB) announced today that 23 abstracts, including 20 abstracts evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, will be presented or published at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, from May 29-June 2, and at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden, from June 11-14.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that together with Kite, a Gilead company, it will present more than 25 abstracts, including six oral presentations, at the 2026 ASCO Annual Meeting (May 29 – June 2) and the 2026 EHA Congress (June 11 – 14). These presentations underscore the increasing diversity of Gilead’s oncology portfolio and pipeline reflecting a growing body of evidence across both solid tumors and hematologic malignancies. Collectively, the data demonstrate Gilead and Kite’s leadership in antibody-drug conjugates (ADCs) and CAR T-cell therapy.

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present multiple abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29–June 2, 2026, in Chicago.

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated therapies for solid tumors, today announced the presentation of safety and efficacy data from the ongoing EVEREST-2 clinical study (NCT06051695). The findings, which are being presented in poster presentations during the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place May 29 – June 2, 2026, in Chicago, include updates on the first reported complete response (CR) in a patient with non-small cell lung cancer (NSCLC) following treatment with A2B694, a logic-gated mesothelin (MSLN)-targeted TmodTM chimeric antigen receptor T-cell (CAR T-cell) therapy.

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha radiopharmaceuticals for cancer, today announced the abstract release for its oral presentation on June 1, at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The abstract describes interim results from Part 3 of the CONVERGE-01 Phase 2 trial of Ac-225 rosopatamab tetraxetan (CONV01-α) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received Lu-177-PSMA radioligand therapy (Lu-PSMA).

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, will present new findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, where the cancer center will showcase 49 abstracts spanning solid tumors and blood cancers.

Flatiron Health today announced its presence at the American Society of Clinical Oncology (ASCO) Annual Meeting happening from May 29 - June 2, 2026, in Chicago, Illinois. Flatiron's high-quality real-world data and innovative research capabilities are featured across 25+ research acceptances, including 14 Flatiron-authored poster presentations and online publications.

Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that the company has received approval from the KRX to proceed with its Initial Public Offering (IPO). The move marks a pivotal transition for the company, supported by a robust pipeline that includes two clinical-stage assets, one of which is IGT-427 (now called MK-8748), an investigational bi-specific antibody (Anti-VEGF/TIE2), for patients with retinal diseases being developed by Merck (known as MSD outside of the US and Canada).

Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX® (cabozantinib), and its investigational oral kinase inhibitor, zanzalintinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 29 – June 2 in Chicago.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new retrospective data showing that Noetik’s artificial intelligence-based TARIO-2 model identified spatial tumor microenvironment patterns associated with clinical outcomes from routine pretreatment tumor pathology images in patients treated with botensilimab (BOT) plus balstilimab (BAL), Agenus’ investigational next-generation multifunctional, Fc-enhanced anti-CTLA-4 and anti-PD-1 immunotherapy combination.

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Veritone, Inc. (NASDAQ: VERI) securities between October 14, 2025 and April 14, 2026. Veritone engages in the provision of artificial intelligence (“AI”) computing solutions and services.

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Pinterest, Inc. (NYSE: PINS) between February 7, 2025 and February 12, 2026. Pinterest describes itself as a “a visual social media platform on which users organize various kinds of content into “boards”, which serve as inspiration for projects the user hopes to complete.”

Daytona International Speedway today announced a transformative, venue-wide LED lighting project that will introduce the next generation of lighting technology to the “World Center of Racing,” marking the next step in how motorsports are experienced by fans, competitors and viewers around the world.

Mayville Engineering Company (NYSE: MEC) (the “Company” or “MEC”), a leading value-added provider of design, prototyping and manufacturing solutions serving diverse end markets, today announced the closing of its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and other offering expenses payable by MEC. This amount includes the exercise in full by the underwriters of their option to purchase up to an additional 652,000 shares of common stock in the offering (the “Option”).

Morgan Stanley (NYSE: MS) today announced the winners of its 17th annual Strategy Challenge, the Firm’s flagship pro bono program which brings together rising talent to help nonprofits solve strategic, mission-critical challenges. The winning teams supported Hour Children in the U.S. and Mental Health Innovations in the UK.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights of its 2026 Invisalign® EMEA Ortho Summit, which brought together approximately 400 orthodontists and dental professionals from across Europe, the Middle East, and Africa (EMEA).

Matador Resources Company (NYSE: MTDR) (“Matador” or the “Company”) announces the successful bolt-on acquisition of 5,154 net undeveloped acres in the core of the Delaware Basin as part of the Bureau of Land Management (BLM) Oil and Gas Lease Sale this week.

Glancy Prongay Wolke & Rotter LLP (“GPWR”), announces that it has filed a class action lawsuit in the United States District Court for the Central District of California, captioned Elwan v. Veritone, Inc., et al., Case No. 8:26-cv-01275, on behalf of persons and entities that purchased or otherwise acquired Veritone, Inc. (“Veritone” or the “Company”) (NASDAQ: VERI) securities between October 14, 2025 and April 14, 2026, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

All Remote — GitLab Inc., the intelligent orchestration platform for DevSecOps, today released GitLab 19.0, expanding secrets management, agentic merge request workflows, CI pipeline visibility, self-hosted open source model support, and supply chain visibility.